Key result
Next-generation mRNA-1283 vaccine is estimated to dominate original mRNA vaccines in cost-effectiveness.
Why the study?
Is the next-generation COVID-19 mRNA-1283 vaccine cost-effective compared to originally-licensed mRNA vaccines in the US?
Is the next-generation COVID-19 mRNA-1283 vaccine cost-effective compared to originally-licensed mRNA vaccines in the US?
The next-generation mRNA-1283 COVID-19 vaccine is projected to be a highly cost-effective alternative to originally-licensed mRNA vaccines in the US.
Supports mRNA-1283 as preferred COVID-19 vaccine in US adults; reinforces prior cost-effectiveness analyses of updated mRNA platforms.
Study results suggest mRNA-1283 may represent a highly cost-effective strategy (considering a $100,000-150,000 per QALY willingness-to-pay threshold) to reduce COVID-19 burden. Based on rVE assumptions made, mRNA-1283 was estimated to dominate originally-licensed mRNA vaccines in this recommended population. mRNA-1283 may provide a valuable option to optimize US COVID-19 immunization programs and protect those most vulnerable.
No takes yet. Share an insight, caveat, or question.
Fust et al. (2026) studied this question. The next-generation mRNA-1283 vaccine is estimated to be highly cost-effective and dominate original mRNA vaccines at a $100,000-150,000 per QALY threshold in the US.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: